Osteoporosis — A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
Citation(s)
Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis